NDANASALSPRAY, METERED
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
XHANCE (fluticasone propionate) by Paratek Pharmaceuticals is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of fluticasone propionate ointment, 0. Approved for asthma. First approved in 2017.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XHANCE is a metered nasal spray formulation of fluticasone propionate approved by the FDA in September 2017 for treating symptoms of hay fever and other upper respiratory allergies. The drug works through corticosteroid mechanisms that modulate signaling, immune function, inflammation, and protein regulation, though the precise mechanism in this nasal formulation remains incompletely characterized. As a nasal spray, XHANCE represents an alternative delivery route to inhaled or topical fluticasone products, positioning it within the intranasal corticosteroid class for allergic rhinitis management.
$0.0BPart D
9.8 years to LOEMechanism of Action
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of fluticasone propionate ointment, 0.005% in corticosteroid-responsive dermatoses is unknown.
Indications (1)
Clinical Trials (20)
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
Started May 2026
304 enrolled
Asthma
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Started Dec 2024
724 enrolled
Asthma
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
Started May 2024
30 enrolled
Asthma
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Started Aug 2023
2,700 enrolled
Asthma
Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Started Aug 2023
34 enrolled
Bioequivalence
Worked on XHANCE at Paratek Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.